Page last updated: 2024-11-05

ytterbium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ytterbium is a rare earth element with a silvery-white metallic appearance. It is not found free in nature, but is present in various minerals like gadolinite and euxenite. Ytterbium is produced by separating it from other rare earth elements through a complex process involving ion exchange and solvent extraction. It exhibits a wide range of applications, including:

* **Laser technology:** Ytterbium-doped fibers are used in high-power lasers for industrial applications, such as cutting, welding, and marking materials.
* **Optical communication:** Ytterbium-doped fibers are also used in fiber optic amplifiers for boosting optical signals in telecommunication networks.
* **Medical imaging:** Ytterbium isotopes are employed in magnetic resonance imaging (MRI) as contrast agents to enhance image quality.
* **Metallurgy:** Ytterbium alloys find uses in various fields, such as aerospace and nuclear technology.

Ytterbium is studied extensively for its potential in diverse fields due to its unique properties, such as:

* **High melting point:** Ytterbium has a relatively high melting point, making it suitable for high-temperature applications.
* **Optical properties:** Ytterbium exhibits specific optical properties that make it valuable for lasers and fiber optics.
* **Magnetic properties:** Ytterbium exhibits magnetic properties that are being explored for applications in magnetic materials and devices.

The ongoing research on ytterbium aims to further explore its potential in areas like renewable energy, quantum computing, and advanced materials. '

Ytterbium: An element of the rare earth family of metals. It has the atomic symbol Yb, atomic number 70, and atomic weight 173. Ytterbium has been used in lasers and as a portable x-ray source. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23992
CHEBI ID33381
MeSH IDM0023108

Synonyms (74)

Synonym
YB ,
70yb
yterbio
CHEBI:33381 ,
7440-64-4
ytterbium
ytterbium, chunks, 99.9% trace metals basis
einecs 231-173-2
yb2 ,
ytterbium (ii) ion
unii-mnq4o4wsi1
mnq4o4wsi1 ,
ytterbium, elemental
ytterbium [mi]
ytterbium [who-dd]
ytterbium [vandf]
NAWDYIZEMPQZHO-UHFFFAOYSA-N
DTXSID4046993 ,
AKOS024257647
ytterbium foil, 0.3mm (0.01in) thick
ytterbium foil, 0.64mm (0.025in) thick
ytterbium foil, 0.1mm (0.004in) thick
ytterbium ingot
ytterbium foil, 1.0mm (0.04in) thick
ytterbium powder, -200 mesh
ytterbium powder
mfcd00011286
ytterbium foil, 3n
ytterbium ingot, 3n
ytterbium chips, 3n
ytterbium, foil, thickness 0.80 mm, size 30 x 30 mm, purity 99%
ytterbium, rod, 100mm, diameter 6.35mm, cast, 99%
ytterbium, foil, 24x24mm, thickness 0.80mm, as rolled, 99%
ytterbium, lump, 100g, max. size 25mm, 99.9%
ytterbium, wire reel, 300mm, diameter 1.0mm, square section, 99.9%
ytterbium, wire reel, 50mm, diameter 1.0mm, square section, 99.9%
ytterbium, foil, thickness 0.80 mm, size 60 x 60 mm, purity 99%
ytterbium, wire reel, 100mm, diameter 1.0mm, square section, 99.9%
ytterbium, foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%
ytterbium, foil, not light tested, 25x25mm, thickness 0.025mm, as rolled, 99%
ytterbium, rod, 100mm, diameter 10.0mm, cast, 99%
ytterbium, powder, max. particle size 500 micron, weight 10 g, purity 99.9%
ytterbium, wire, 1.0 mm diameter, length 50 mm, purity 99.9%
ytterbium, rod, 50mm, diameter 10.0mm, cast, 99%
ytterbium, foil, 50x50mm, thickness 0.125mm, as rolled, 99%
ytterbium, rod, 50mm, diameter 2.0mm, cast, 99%
ytterbium, foil, 25x25mm, thickness 0.25mm, as rolled, 99%
ytterbium, lump, 50g, max. size 25mm, 99.9%
ytterbium, foil, not light tested, 25x25mm, thickness 0.005mm, as rolled, 99%
ytterbium, lump, 25g, max. size 25mm, 99.9%
ytterbium, wire reel, 200mm, diameter 1.0mm, square section, 99.9%
ytterbium, rod, 50mm, diameter 6.35mm, cast, 99%
ytterbium, foil, 50x50mm, thickness 0.25mm, as rolled, 99%
ytterbium, powder, 500 max. part. size (micron), weight 20 g, purity 99.9%
ytterbium, wire, 1.0 mm diameter, length 100 mm, purity 99.9%
ytterbium, foil, 25x25mm, thickness 0.125mm, as rolled, 99%
ytterbium, foil, 49x49mm, thickness 0.80mm, as rolled, 99%
ytterbium(2+)
Q27115621
ytterbium sputtering target, 76.2mm dia x 3.18mm thick
ytterbium sputtering target, 76.2mm dia x 1.59mm thick
ytterbium sputtering target, 50.8mm dia x 1.59mm thick
ytterbium nanofoil
AMY22275
ultra thin ytterbium nanofoil
barium sulfide (bas) sputtering targets
ytterbium pieces, sublimed, 99.9% (reo)
ytterbium standard: yb @ 1000 microg/ml in 5% hno3
ytterbium standard: yb @ 10000 microg/ml in 5% hno3
ytterbium chunks
SY077197
ytterbium metallicum
dtxcid2026993
ytterbium - yb @ 1000 microg/ml in 5% hno3

Research Excerpts

Overview

Ytterbium-169 (169Yb) is a promising new intermediate low-energy isotope for interstitial implantation. It has a half life of 32 days and an average photon energy of 93 KeV.

ExcerptReferenceRelevance
"Ytterbium oxide proved to be a properly radiopacifying agent for calcium silicate-based cement since it did not affected the physicochemical and biological properties besides preserving the bioactive potential of this material."( Ytterbium Oxide as Radiopacifier of Calcium Silicate-Based Cements. Physicochemical and Biological Properties.
Bonetti-Filho, I; Bosso-Martelo, R; Costa, BC; Guerreiro-Tanomaru, JM; Rodrigues, EM; Tanomaru-Filho, M,
)
2.3
"Ytterbium-169 (169Yb) is a promising new intermediate low-energy isotope for interstitial implantation. "( A secondary air kerma strength standard for Yb-169 interstitial brachytherapy sources.
Das, RK; Meigooni, AS; Mishra, V; Perera, H; Williamson, JF, 1995
)
1.73
"Ytterbium-169 (169Yb) is a promising new isotope for brachytherapy with a half life of 32 days and an average photon energy of 93 KeV. "( Dosimetric characteristics, air-kerma strength calibration and verification of Monte Carlo simulation for a new Ytterbium-169 brachytherapy source.
Li, Z; Meigooni, AS; Mishra, V; Perera, H; Williamson, JF, 1994
)
1.94
"Ytterbium169 is a radiolanthanide with a period of 32 days."( [Value of isotope study with ytterbium-169 citrate in the diagnosis of pulmonary opacities of cancerous nature].
Chatal, JF; Corroller, J; Guihard, R; Moigneteau, C; Peltier, P, 1978
)
1.27

Effects

ExcerptReferenceRelevance
"Ytterbium-169 has been developed as a possible replacement for Iridium-192 and Iodine-125. "( Microdosimetric single event spectra of Ytterbium-169 compared with commonly used brachytherapy sources and teletherapy beams.
Gillin, MT; Wilson, JF; Zellmer, DL, 1992
)
1.99

Toxicity

ExcerptReferenceRelevance
" In order to evaluate possible toxic effects of scandium, chromium, lanthanum, samarium, europium, dysprosium, terbium, thulium, and ytterbium oxides, and barium sulfate upon growth, general development, reproduction, and lactation, mice were fed different levels of these compounds for three generations."( Studies of nutritional safety of some heavy metals in mice.
Gray, DH; Hutcheson, DP; Luckey, TD; Venugopal, B, 1975
)
0.46
" The inhibition was dependent on the actual amount of toxic Yb uptake by the cucumber plants."( Comparative toxicity of nanoparticulate/bulk Yb₂O₃ and YbCl₃ to cucumber (Cucumis sativus).
Chai, Z; Ding, Y; Guo, Z; He, X; Ma, Y; Tai, R; Zhang, P; Zhang, Z; Zhao, Y, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies demonstrated that concentrations of 90Y-labeled B72."( Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Cheung, L; Gano, J; Kavanagh, JJ; Kudelka, AP; Murray, JL; Rosenblum, MG; Verschraegen, CF, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
"33 mg per meal); on day 2, identical meals (taken with a calcium supplement to reduce iron bioavailability) were given with equivalent amounts of 58Fe-labeled iron and ytterbium; on day 3, a well-absorbed reference dose of 54Fe (3 mg) was given with 1 mg Dy."( Rare earth elements as nonabsorbable fecal markers in studies of iron absorption.
Crews, HM; Eagles, J; Fairweather-Tait, SJ; Minihane, AM; Owen, L, 1997
)
0.49
"0-tesla MR system in accordance with the safety limits of the specific absorption rate (SAR)."( Ytterbium-based PARACEST agent: feasibility of CEST imaging on a clinical MR scanner.
Burdinski, D; Hatakenaka, M; Honda, H; Kato, N; Keupp, J; Nakayama, T; Nishie, A; Takayama, Y; Yoshise, S; Yoshiura, T, 2012
)
1.82

Dosage Studied

Ytterbium chloride (Yb) is an indicator of fecal output. We dosed 13 mature beef cows with Yb and chromic oxide (Cr2O3) daily. Rate of passage from the rumen was estimated. Four crossbred heifers were dosed with cobalt ethylenediaminetetraacetic acid.

ExcerptRelevanceReference
"Rate of passage from the rumen was estimated from samples from the rumen, duodenum, ileum, and rectum after four crossbred heifers were dosed with cobalt ethylenediaminetetraacetic acid and ytterbium-labeled alfalfa or corn grain as digesta markers."( Effects of sampling site on passage rate estimates in heifers fed alfalfa hay or a high concentrate diet.
Goetsch, AL; Owens, FN, 1985
)
0.46
" Five-hr marker excretions as a percent of that originally dosed were similar (P greater than ."( Comparison of ferric oxide and ytterbium chloride as digesta markers in broiler chicks.
Sarani, S; Smith, MO; Teeter, TG, 1985
)
0.56
"To assess the potential of ytterbium chloride (Yb) as an indicator of fecal output, we dosed 13 mature beef cows with Yb and chromic oxide (Cr2O3) either once (0800) or twice (0800 and 1600 hr) daily."( Comparison of ytterbium chloride and chromium sesquioxide as fecal indicators.
Prigge, EC; Reid, RL; Varga, GA; Vicini, JL, 1981
)
0.92
"79% of Cr dosed intraruminally was secreted or excreted in milk and urine in the 48-h period following marker administration."( Short communication: Comparison of 3 solid digesta passage markers in dairy cows.
Hristov, AN; Lee, C, 2014
)
0.4
" In addition to high-contrast imaging and consequently high sensitivity detection of bladder cancer cells, highly selective optoporation-assisted chemotherapy was accomplished using a dosage of chemotherapy agent significantly lower than any previous reports, within a clinically relevant incubation time window."( Multifunctional nanoclusters of NaYF
Cho, SK; Flaig, TW; Mao, C; Park, W; Su, LJ; Wolenski, CD, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
lanthanoid atom
f-block element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,340)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990302 (22.54)18.7374
1990's72 (5.37)18.2507
2000's300 (22.39)29.6817
2010's581 (43.36)24.3611
2020's85 (6.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.40 (24.57)
Research Supply Index7.24 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index151.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (0.79%)5.53%
Reviews18 (1.30%)6.00%
Case Studies14 (1.01%)4.05%
Observational1 (0.07%)0.25%
Other1,341 (96.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]